BioWorld Asia

Feb. 10, 2010

First Deal for Apeiron a Doozy: Getting up to $329M from GSK

Apeiron Biologics AG licensed its lead program APN01, a recombinant form of human angiotensin converting enzyme 2 (ACE2), to London-based GlaxoSmithKline plc in a deal valued at up to €236 million (US$329.4 million). (BioWorld International) Read More

Cancer Research Charity Signs AstraZeneca Discovery Pact

Vaccine for Maternal Malaria May be Possible as Soon as 10 Years

NewCo News: Sistemic Raises $1M to Fund New Drug Discovery Platform

NeuroSearch Rockets on Good Phase III Data for Huntington's

Isotechnika 'Lux' Out; Partner Files First Voclosporin NDA

Bankers Predict 25% Growth for U.S. IPO Market This Year

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 13, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

HX-16108 holds promise for treating inflammatory skin diseases

BioWorld Science

Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...